Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder - Preliminary findings
Autore:
Mundo, E; Walker, M; Cate, T; Macciardi, F; Kennedy, JL;
Indirizzi:
Univ Toronto, Neurogenet Sect, Ctr Addict & Mental Hlth, Toronto, ON M5T 1R8, Canada Univ Toronto Toronto ON Canada M5T 1R8 Hlth, Toronto, ON M5T 1R8, Canada
Titolo Testata:
ARCHIVES OF GENERAL PSYCHIATRY
fascicolo: 6, volume: 58, anno: 2001,
pagine: 539 - 544
SICI:
0003-990X(200106)58:6<539:TROSTP>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
OBSESSIVE-COMPULSIVE DISORDER; FUNCTIONAL POLYMORPHISM; REUPTAKE INHIBITORS; AFFECTIVE-ILLNESS; DEPRESSION; ASSOCIATION; PROMOTER; INDUCTION; FLUVOXAMINE; EFFICACY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Clinical Medicine
Life Sciences
Citazioni:
43
Recensione:
Indirizzi per estratti:
Indirizzo: Kennedy, JL Univ Toronto, Neurogenet Sect, Ctr Addict & Mental Hlth, R-31,Clarke Site,250 Coll St, Toronto, ON M5T 1R8, Canada Univ Toronto R-31,Clarke Site,250 Coll St Toronto ON Canada M5T 1R8
Citazione:
E. Mundo et al., "The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder - Preliminary findings", ARCH G PSYC, 58(6), 2001, pp. 539-544

Abstract

Background: II-he occurrence of mania during antidepressant treatment is akey issue in the clinical management of bipolar disorder (BP). The serotonin transporter (5-HTT) is the selective site of action of most proserotonergic compounds used to treat bipolar depression. The 5-HTT gene (SLC6A4) has2 known polymorphisms. The aim of this study was to investigate the role of the SLC6A4 variants in the pathogenesis of antidepressant-induced mania in BP. Methods: Twenty-seven patients with a DSM-IV diagnosis of BP I or II, withat least 1 manic or hypomanic episode induced by treatment with proserotonergic antidepressants (IM+ group), were compared with 29 unrelated, matchedpatients with a diagnosis of BP I or II, who had been exposed to proserotonergic antidepressants without development of manic or hypomanic symptoms (IM- group). The 2 known polymorphisms of the SLC6A4 were genotyped, and allelic and genotypic association analyses were performed. Results: With respect to the polymorphism in the promoter region (5HTTLPR), IM+ patients had an excess of the short allele (n=34 [63%]) compared withIM- patients (n=17 [29%]) (chi (2)(1), 12.77; P < .001). The genotypic association analysis showed a higher rate of homozygosity for the short variant in the IM+ group (n=10 [37%]) than in the IM- group (n=2 [7%]) and a lower rate of homozygosity for the long variant in the IM+ group (n = 3 [11%]) compared with the IM- group (n=14 [48%]) (chi (2)(2), 12.43; P=.002). No associations were found for the polymorphism involving a variable number of tandem repeats. Conclusion: If these results are replicated, the 5HTTLPR polymorphism may become an important predictor of abnormal response to medication in patients with BP.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/04/20 alle ore 10:52:06